Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

Presentation TCT 2022

TCT 333: Effect of stroke on readmissions and cardiovascularoutcomes in patients with Mitraclip.

Presenter: Nirav Patel

September 19, 2022

Presentation TCT 2022

TCT 332: Clinical outcome of transcatheter aortic valve replacement with TriGUARD 3™ cerebral embolic protection device

Presenter: Sayonara Daal

September 19, 2022

Presentation TCT 2022

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

Presenter: Yeonwoo Choi

September 19, 2022

Presentation TCT 2022

TCT 329: Cerebral Embolic Protection Devices For Prevention Of Post-Procedural Ischemic Stroke With Transcatheter Aortic Valve Replacement: A SYSTEMATIC REVIEW AND META-ANALYSIS

Presenter: Tanesh Ayyalu

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation TCT 2022

TCT 327: Clinical and Radiographic Measures of Stroke-Related Outcomes with Cerebral Embolic Protection Devices During TAVR: A Meta-analysis.

Presenter: Arpanjeet Kaur

September 18, 2022

Presentation TCT 2022

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

Presenter: Alexandra J. Lansky

September 17, 2022

Presentation TCT 2022

New and Novel CEP Devices: Differentiating Features

Presenter: Giora Weisz

September 17, 2022

Presentation TCT 2022

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Presenter: David J. Cohen

September 17, 2022

Presentation TCT 2022

Selective Use: Only in Vulnerable Patients

Presenter: John K. Forrest

September 17, 2022

Presentation TCT 2022

Systematic Use: Unravelling the Stroke Story

Presenter: Nicolas M. Van Mieghem

September 17, 2022

Presentation TCT 2022

The British Heart Foundation PROTECT TAVI Trial: The Next Round!

Presenter: Daniel J. Blackman

September 17, 2022

Presentation TCT 2022

Other Registry Findings and PROTECTED TAVR: Concordant or Divergent

Presenter: Raj Makkar

September 17, 2022

Presentation TCT 2022

The Journey of CEP from Clean TAVI to PROTECTED TAVR: Lessons Learned

Presenter: Axel Linke

September 17, 2022

Presentation TCT 2022

Clinical Implications of PROTECTED TAVR: A Neurologist’s Perspective

Presenter: Steven Messe

September 17, 2022

Presentation TCT 2022

PROTECTED TAVR: My Take-Home Messages & Some "Dirty Little Secrets"

Presenter: Samir Kapadia

September 17, 2022

Presentation TCT 2022

Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: The PROTECTED TAVR Study

Presenter: Samir Kapadia

September 17, 2022

Presentation TCT 2022

TCT 324: Cerebral Embolic Protection Devices and Outcomes of Transcatheter Aortic Valve Replacement: Insight from National Readmission Database 2017-2019.

Presenter: Ahmed Altibi

September 17, 2022

Presentation TCT 2022

Cerebral Embolic Protection: Why, When, and Who?

Presenter: Axel Linke

September 17, 2022

Presentation TVT 2022

Full-Body Embolic Protection With Debris Capture

Presenter: Ran Kornowski

June 10, 2022

Advertisement

TCT 333: Effect of stroke on readmissions and cardiovascularoutcomes in patients with Mitraclip.

TCT 332: Clinical outcome of transcatheter aortic valve replacement with TriGUARD 3™ cerebral embolic protection device

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

TCT 329: Cerebral Embolic Protection Devices For Prevention Of Post-Procedural Ischemic Stroke With Transcatheter Aortic Valve Replacement: A SYSTEMATIC REVIEW AND META-ANALYSIS

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

TCT 327: Clinical and Radiographic Measures of Stroke-Related Outcomes with Cerebral Embolic Protection Devices During TAVR: A Meta-analysis.

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

New and Novel CEP Devices: Differentiating Features

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Selective Use: Only in Vulnerable Patients

Systematic Use: Unravelling the Stroke Story

The British Heart Foundation PROTECT TAVI Trial: The Next Round!

Other Registry Findings and PROTECTED TAVR: Concordant or Divergent

The Journey of CEP from Clean TAVI to PROTECTED TAVR: Lessons Learned

Clinical Implications of PROTECTED TAVR: A Neurologist’s Perspective

PROTECTED TAVR: My Take-Home Messages & Some "Dirty Little Secrets"

Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: The PROTECTED TAVR Study

TCT 324: Cerebral Embolic Protection Devices and Outcomes of Transcatheter Aortic Valve Replacement: Insight from National Readmission Database 2017-2019.

Cerebral Embolic Protection: Why, When, and Who?

Full-Body Embolic Protection With Debris Capture

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content